JP2019510739A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510739A5
JP2019510739A5 JP2018540415A JP2018540415A JP2019510739A5 JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5 JP 2018540415 A JP2018540415 A JP 2018540415A JP 2018540415 A JP2018540415 A JP 2018540415A JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5
Authority
JP
Japan
Prior art keywords
compound
composition according
mammal
gfral
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/074809 external-priority patent/WO2017147742A1/en
Publication of JP2019510739A publication Critical patent/JP2019510739A/ja
Publication of JP2019510739A5 publication Critical patent/JP2019510739A5/ja
Pending legal-status Critical Current

Links

JP2018540415A 2016-02-29 2016-02-29 Ｇｆｒａｌ受容体療法 Pending JP2019510739A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/074809 WO2017147742A1 (en) 2016-02-29 2016-02-29 Gfral receptor therapies

Publications (2)

Publication Number Publication Date
JP2019510739A JP2019510739A (ja) 2019-04-18
JP2019510739A5 true JP2019510739A5 (enExample) 2019-05-30

Family

ID=59742416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540415A Pending JP2019510739A (ja) 2016-02-29 2016-02-29 Ｇｆｒａｌ受容体療法

Country Status (4)

Country Link
EP (1) EP3423094A4 (enExample)
JP (1) JP2019510739A (enExample)
CN (1) CN108697795A (enExample)
WO (1) WO2017147742A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2017152105A1 (en) * 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
CA3038846A1 (en) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
KR20210081389A (ko) 2018-10-22 2021-07-01 얀센 파마슈티카 엔.브이. 글루카곤 유사 펩티드 1(glp1)-성장 분화 인자 15(gdf15) 융합 단백질 및 이의 용도
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
JP7495529B2 (ja) * 2020-06-04 2024-06-04 テグ キョンプク インスティテュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌ拮抗抗体及びその用途
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
MX2023011655A (es) * 2021-03-31 2023-10-11 Cambridge Entpr Ltd Inhibidores terapeuticos de la se?alizacion de gdf15.
CN117693525A (zh) * 2021-06-30 2024-03-12 上海津曼特生物科技有限公司 抗gfral抗体及其应用
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478369A1 (en) * 2002-03-05 2003-09-18 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US10752664B2 (en) * 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
CN102321173B (zh) * 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MX370720B (es) * 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
WO2017121865A1 (en) * 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof

Similar Documents

Publication Publication Date Title
JP2019510739A5 (enExample)
JP2020536109A5 (enExample)
JP2012525128A5 (enExample)
JP2016512213A5 (enExample)
PE20220938A1 (es) Compuestos agonistas de gipr
JP2019506841A5 (enExample)
JP2020513809A5 (enExample)
JP2018515088A5 (enExample)
RU2015127780A (ru) Агонисты рецепторов глюкагона/glp-1 для лечения ожирения
RU2018107047A (ru) Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
JP2016527286A5 (enExample)
JP2016539096A5 (enExample)
JP2012500006A5 (enExample)
JP2016534052A5 (enExample)
JP2017113019A5 (enExample)
JP2014221758A5 (enExample)
JP2017510567A5 (enExample)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP2018535948A5 (enExample)
JP2017500018A5 (enExample)
JP2016537340A5 (enExample)
JP2017522903A5 (enExample)
FI3569620T3 (fi) Ihmisen cgrp-reseptoria sitovat vasta-aineet
JP2016519650A5 (enExample)
JP2015522252A5 (enExample)